In addition, considering the recent data on the efficacy of lorlatinib even in controlling the distant metastases localized in the central nervous system [50], it would have been interesting to evaluate its activity in ALK-RCC patients either after progression on a previous ALK-i or as a first-line treatment. This evidence concerns the gene ALK and renal cell adenocarcinoma.